Research Analysts Set Expectations for RNTX FY2026 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – HC Wainwright dropped their FY2026 EPS estimates for Rein Therapeutics in a report released on Thursday, April 2nd. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($1.63) for the year, down from their prior forecast of ($0.80). The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.46) EPS and FY2029 earnings at ($1.22) EPS.

Rein Therapeutics (NASDAQ:RNTX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.12).

Several other brokerages have also recently commented on RNTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered Rein Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Rein Therapeutics currently has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Trading Up 11.2%

Rein Therapeutics stock traded up $0.16 during mid-day trading on Tuesday, hitting $1.55. The stock had a trading volume of 202,784 shares, compared to its average volume of 108,152. The stock has a 50-day simple moving average of $1.24 and a two-hundred day simple moving average of $1.30. The stock has a market capitalization of $43.32 million, a PE ratio of -0.77 and a beta of 1.40. Rein Therapeutics has a 12 month low of $1.02 and a 12 month high of $2.40.

Institutional Trading of Rein Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RNTX. Voss Capital LP raised its stake in shares of Rein Therapeutics by 86.0% during the 3rd quarter. Voss Capital LP now owns 2,666,532 shares of the company’s stock worth $3,053,000 after purchasing an additional 1,232,846 shares in the last quarter. Prosight Management LP increased its holdings in Rein Therapeutics by 32.7% during the third quarter. Prosight Management LP now owns 567,898 shares of the company’s stock worth $650,000 after buying an additional 139,979 shares during the last quarter. Gagnon Securities LLC raised its position in Rein Therapeutics by 218.8% during the third quarter. Gagnon Securities LLC now owns 228,692 shares of the company’s stock worth $262,000 after acquiring an additional 156,947 shares in the last quarter. Gleason Group Inc. bought a new position in shares of Rein Therapeutics in the 3rd quarter valued at about $26,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Rein Therapeutics during the 2nd quarter worth about $68,000. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.